So, an ETF with a phytomedical research and biopharmaceutical drug development company?
Targeting Cytokine release syndrome, or CRS...potential to reset the body’s immune system after triggering hyperinflammation. Post-exposure target population...
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.